Skip to main content

Table 1 Patient characteristics

From: Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer

Cohort

 Number of patients

22

 Number of collections

40

Sex

 Female

22 (100%)

Pathology

 IDC

18 (81.8%)

 ILC

4 (18.2%)

Histologic subtype

 HR+, HER2−

17 (77.3%)

 HR−, HER2+

1 (4.5%)

 HR+, HER2+

1 (4.5%)

 TNBC

3 (13.6%)

Clinical subtype

 IBC

6 (27.3%)

 Non-IBC

16 (72.7%)

Prior therapies in metastatic setting

2* [0–7]

Sites of disease

 Bone

18 (81.8%)

 Visceral

15 (68.2%)

CTC clusters

 Yes

8 (36.4%)

 No

14 (63.6%)

 Total blood draws with clusters

14 (35.0%)

  1. IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, HR hormone receptor, TNCB triple-negative breast cancer, IBC inflammatory breast cancer
  2. *The median